Histone deacetylases and epigenetic therapies of hematological malignancies

Research output: Contribution to journalArticle

Abstract

Histone deacetylase inhibitors (HDACi) represent a novel class of targeted drugs which alter the acetylation status of several cellular proteins. These agents, modulating both chromatin structure through histone acetylation, and the activity of several non-histone substrates, are at the same time able to determine changes in gene transcription and to induce a plethora of biological effects ranging from cell death induction, to differentiation, angiogenesis inhibition or modulation of immune responses. The impressive anticancer activity observed in both in vitro and in vivo cancer models, together with their preferential effect on cancer cells, have led to a huge effort into the identification and development of HDACi with different characteristics.To date, several clinical trials of HDACi conducted in solid tumors and hematological malignancies have shown a preferential clinical efficacy of these drugs in hematological malignancies, and in particular in cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), Hodgkin lymphoma (HL) and myeloid malignancies.Several agents are also beginning to be tested in combination therapies, either as chemo sensitizing agents in association with standard chemotherapy drugs or in combination with DNA methyltransferase inhibitors (DNMTi) in the context of the so-called " epigenetic therapies" , aimed to revert epigenetic alterations found in cancer cells. Herein, we will review HDACi data in hematological malignancies questioning the molecular basis of observed clinical responses, and highlighting some of the concerns raised on the use of these drugs for cancer therapy.

Original languageEnglish
Pages (from-to)18-34
Number of pages17
JournalPharmacological Research
Volume62
Issue number1
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Histone Deacetylases
Hematologic Neoplasms
Epigenomics
Histone Deacetylase Inhibitors
Neoplasms
Acetylation
Therapeutics
Pharmaceutical Preparations
Peripheral T-Cell Lymphoma
Drug Therapy
Cutaneous T-Cell Lymphoma
Methyltransferases
Hodgkin Disease
Histones
Chromatin
Cell Death
Clinical Trials
DNA
Genes
Proteins

Keywords

  • Acute myeloid leukemia
  • Chromatin
  • Epigenetic therapy
  • HDACi
  • Leukemia
  • Lymphoma

ASJC Scopus subject areas

  • Pharmacology

Cite this

Histone deacetylases and epigenetic therapies of hematological malignancies. / Mercurio, Ciro; Minucci, Saverio; Pelicci, Pier Giuseppe.

In: Pharmacological Research, Vol. 62, No. 1, 07.2010, p. 18-34.

Research output: Contribution to journalArticle

@article{2a366a0736794714a6665892053be439,
title = "Histone deacetylases and epigenetic therapies of hematological malignancies",
abstract = "Histone deacetylase inhibitors (HDACi) represent a novel class of targeted drugs which alter the acetylation status of several cellular proteins. These agents, modulating both chromatin structure through histone acetylation, and the activity of several non-histone substrates, are at the same time able to determine changes in gene transcription and to induce a plethora of biological effects ranging from cell death induction, to differentiation, angiogenesis inhibition or modulation of immune responses. The impressive anticancer activity observed in both in vitro and in vivo cancer models, together with their preferential effect on cancer cells, have led to a huge effort into the identification and development of HDACi with different characteristics.To date, several clinical trials of HDACi conducted in solid tumors and hematological malignancies have shown a preferential clinical efficacy of these drugs in hematological malignancies, and in particular in cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), Hodgkin lymphoma (HL) and myeloid malignancies.Several agents are also beginning to be tested in combination therapies, either as chemo sensitizing agents in association with standard chemotherapy drugs or in combination with DNA methyltransferase inhibitors (DNMTi) in the context of the so-called {"} epigenetic therapies{"} , aimed to revert epigenetic alterations found in cancer cells. Herein, we will review HDACi data in hematological malignancies questioning the molecular basis of observed clinical responses, and highlighting some of the concerns raised on the use of these drugs for cancer therapy.",
keywords = "Acute myeloid leukemia, Chromatin, Epigenetic therapy, HDACi, Leukemia, Lymphoma",
author = "Ciro Mercurio and Saverio Minucci and Pelicci, {Pier Giuseppe}",
year = "2010",
month = "7",
doi = "10.1016/j.phrs.2010.02.010",
language = "English",
volume = "62",
pages = "18--34",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "1",

}

TY - JOUR

T1 - Histone deacetylases and epigenetic therapies of hematological malignancies

AU - Mercurio, Ciro

AU - Minucci, Saverio

AU - Pelicci, Pier Giuseppe

PY - 2010/7

Y1 - 2010/7

N2 - Histone deacetylase inhibitors (HDACi) represent a novel class of targeted drugs which alter the acetylation status of several cellular proteins. These agents, modulating both chromatin structure through histone acetylation, and the activity of several non-histone substrates, are at the same time able to determine changes in gene transcription and to induce a plethora of biological effects ranging from cell death induction, to differentiation, angiogenesis inhibition or modulation of immune responses. The impressive anticancer activity observed in both in vitro and in vivo cancer models, together with their preferential effect on cancer cells, have led to a huge effort into the identification and development of HDACi with different characteristics.To date, several clinical trials of HDACi conducted in solid tumors and hematological malignancies have shown a preferential clinical efficacy of these drugs in hematological malignancies, and in particular in cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), Hodgkin lymphoma (HL) and myeloid malignancies.Several agents are also beginning to be tested in combination therapies, either as chemo sensitizing agents in association with standard chemotherapy drugs or in combination with DNA methyltransferase inhibitors (DNMTi) in the context of the so-called " epigenetic therapies" , aimed to revert epigenetic alterations found in cancer cells. Herein, we will review HDACi data in hematological malignancies questioning the molecular basis of observed clinical responses, and highlighting some of the concerns raised on the use of these drugs for cancer therapy.

AB - Histone deacetylase inhibitors (HDACi) represent a novel class of targeted drugs which alter the acetylation status of several cellular proteins. These agents, modulating both chromatin structure through histone acetylation, and the activity of several non-histone substrates, are at the same time able to determine changes in gene transcription and to induce a plethora of biological effects ranging from cell death induction, to differentiation, angiogenesis inhibition or modulation of immune responses. The impressive anticancer activity observed in both in vitro and in vivo cancer models, together with their preferential effect on cancer cells, have led to a huge effort into the identification and development of HDACi with different characteristics.To date, several clinical trials of HDACi conducted in solid tumors and hematological malignancies have shown a preferential clinical efficacy of these drugs in hematological malignancies, and in particular in cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), Hodgkin lymphoma (HL) and myeloid malignancies.Several agents are also beginning to be tested in combination therapies, either as chemo sensitizing agents in association with standard chemotherapy drugs or in combination with DNA methyltransferase inhibitors (DNMTi) in the context of the so-called " epigenetic therapies" , aimed to revert epigenetic alterations found in cancer cells. Herein, we will review HDACi data in hematological malignancies questioning the molecular basis of observed clinical responses, and highlighting some of the concerns raised on the use of these drugs for cancer therapy.

KW - Acute myeloid leukemia

KW - Chromatin

KW - Epigenetic therapy

KW - HDACi

KW - Leukemia

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=77952853306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952853306&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2010.02.010

DO - 10.1016/j.phrs.2010.02.010

M3 - Article

C2 - 20219679

AN - SCOPUS:77952853306

VL - 62

SP - 18

EP - 34

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -